<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>glimepiride - Le Fonti New Pharma Italy</title>
	<atom:link href="https://www.newpharmaitaly.it/tag/glimepiride/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/tag/glimepiride/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Tue, 19 Feb 2019 11:51:36 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg</url>
	<title>glimepiride - Le Fonti New Pharma Italy</title>
	<link>https://www.newpharmaitaly.it/tag/glimepiride/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>CAROLINA®, lo studio di Boehringer Ingelheim e Lilly</title>
		<link>https://www.newpharmaitaly.it/carolina-lo-studio-di-boehringer-ingelheim-e-lilly/</link>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Tue, 19 Feb 2019 11:51:36 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[CAROLINA®]]></category>
		<category><![CDATA[Diabete]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[glimepiride]]></category>
		<category><![CDATA[Jeff Emmick]]></category>
		<category><![CDATA[linagliptin]]></category>
		<category><![CDATA[Waheed Jamal]]></category>
		<guid isPermaLink="false">https://www.newpharmaitaly.it/?p=3518</guid>

					<description><![CDATA[<p>Con un follow-up mediano di oltre 6 anni, CAROLINA® ha prodotto ulteriori evidenze che confermano il profilo di sicurezza di lungo termine di linagliptin Boehringer Ingelheim ed Eli Lilly and Company annunciano che lo studio CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) ha raggiunto l’endpoint primario, definito come non-inferiorità [&#8230;]</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/carolina-lo-studio-di-boehringer-ingelheim-e-lilly/">CAROLINA®, lo studio di Boehringer Ingelheim e Lilly</a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
